Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H27NO4S |
Molecular Weight | 365.487 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[S@@+]([O-])CC[C@](CO)(C(=O)O[C@H]1CN2CCC1CC2)C3=CC=CC=C3
InChI
InChIKey=VGXACJMXDYPFDB-SXMMONRFSA-N
InChI=1S/C19H27NO4S/c1-25(23)12-9-19(14-21,16-5-3-2-4-6-16)18(22)24-17-13-20-10-7-15(17)8-11-20/h2-6,15,17,21H,7-14H2,1H3/t17-,19+,25+/m0/s1
Molecular Formula | C19H27NO4S |
Molecular Weight | 365.487 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Revatropate is a muscarinic antagonist with selectivity for M1 and M3 receptor subtypes. Significant improvement in airway function was shown in horses with heaves after inhalation of revatropate, and it was found to be a safe and effective bronchodilator. Early clinical studies in chronic obstructive airway disease (COAD) patients also showed that inhaled revatropate was an effective bronchodilator, and well tolerated.
Originator
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:32:11 GMT 2023
by
admin
on
Sat Dec 16 16:32:11 GMT 2023
|
Record UNII |
3W7L15V40W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Sat Dec 16 16:32:12 GMT 2023 , Edited by admin on Sat Dec 16 16:32:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000080574
Created by
admin on Sat Dec 16 16:32:12 GMT 2023 , Edited by admin on Sat Dec 16 16:32:12 GMT 2023
|
PRIMARY | |||
|
3W7L15V40W
Created by
admin on Sat Dec 16 16:32:12 GMT 2023 , Edited by admin on Sat Dec 16 16:32:12 GMT 2023
|
PRIMARY | |||
|
9554797
Created by
admin on Sat Dec 16 16:32:12 GMT 2023 , Edited by admin on Sat Dec 16 16:32:12 GMT 2023
|
PRIMARY | |||
|
SUB10293MIG
Created by
admin on Sat Dec 16 16:32:12 GMT 2023 , Edited by admin on Sat Dec 16 16:32:12 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105235
Created by
admin on Sat Dec 16 16:32:12 GMT 2023 , Edited by admin on Sat Dec 16 16:32:12 GMT 2023
|
PRIMARY | |||
|
C75283
Created by
admin on Sat Dec 16 16:32:12 GMT 2023 , Edited by admin on Sat Dec 16 16:32:12 GMT 2023
|
PRIMARY | |||
|
C105222
Created by
admin on Sat Dec 16 16:32:12 GMT 2023 , Edited by admin on Sat Dec 16 16:32:12 GMT 2023
|
PRIMARY | |||
|
7425
Created by
admin on Sat Dec 16 16:32:12 GMT 2023 , Edited by admin on Sat Dec 16 16:32:12 GMT 2023
|
PRIMARY | |||
|
149926-91-0
Created by
admin on Sat Dec 16 16:32:12 GMT 2023 , Edited by admin on Sat Dec 16 16:32:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|